Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial

Per Svenningsson, Anders Johansson, Dag Nyholm, Panagiota Tsitsi, Fredrik Hansson, Clas Sonesson, Joakim Tedroff, Per Svenningsson, Anders Johansson, Dag Nyholm, Panagiota Tsitsi, Fredrik Hansson, Clas Sonesson, Joakim Tedroff

Abstract

IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson's disease (PD). The primary objective was to investigate the safety and tolerability of IRL790 in PD patients with LID in a randomized controlled trial. PD patients with peak-dose dyskinesia were randomized to placebo or IRL790 treatment (1:3 ratio) for 4 weeks. Study drug was given as an adjunct treatment to the patients' regular stable antiparkinsonian medication. Dosing was individually titrated for 14 days, whereafter dosing was kept stable for an additional 14 days. Fifteen patients were randomized to treatment and 13 patients completed the 4-week treatment. Adverse events were mostly reported during the titration phase of the trial. They were mainly central nervous system related and could be mitigated by dose adjustments. There were no serious adverse events. There were no clinically significant changes in vital signs, electrocardiogram, and laboratory parameters due to the treatment. The average dose in the stable dose phase was 18 mg daily, yielding a 2-h post-dose plasma concentration of average 229 nM on day 28. Assessments for motor function showed a numeric reduction in dyskinesia. It is concluded that IRL790 can be safely administered to patients with advanced PD. The results will be of guidance for the design of phase 2 studies.

Conflict of interest statement

F.H., C.S., and J.T. are employed by the sponsor, Integrative Research Laboratories A.B. P.S., D.N., A.J., and P.T. declare no competing interests.

Figures

Fig. 1
Fig. 1
Overview of trial profile
Fig. 2
Fig. 2
Number of adverse events (AEs) belonging to the system organ classes nervous system and psychiatric disorders reported during the titration phase (day 1–14), and following stable dosing (day 15–28)

References

    1. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology. 1991;41:202–205. doi: 10.1212/WNL.41.2_Part_1.202.
    1. PD Med Collaborative Group. Gray R, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196–1205. doi: 10.1016/S0140-6736(14)60683-8.
    1. Cenci MA, Ohlin KE, Odin P. Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson’s disease. Cns. Neurol. Disord. Drug. Targets. 2011;10:670–684. doi: 10.2174/187152711797247885.
    1. Picconi B., Hernández L. F., Obeso J. A., Calabresi P. Motor complications in Parkinson’s disease: Striatal molecular and electrophysiological mechanisms of dyskinesias. Mov Disord. Published online 8 December 2017.
    1. Bordet R, et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. Usa. 1997;94:3363–3367. doi: 10.1073/pnas.94.7.3363.
    1. Guillin O, et al. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature. 2001;411:86–89. doi: 10.1038/35075076.
    1. Bézard E, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 2003;9:762–767. doi: 10.1038/nm875.
    1. Guigoni C, et al. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Park. Relat. Disord. 2005;11(Suppl 1):S25. doi: 10.1016/j.parkreldis.2004.11.005.
    1. Solís O, Garcia-Montes JR, González-Granillo A, Xu M, Moratalla R. Dopamine D3 receptor modulates l-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling. Cereb. Cortex. 2017;27:435–446.
    1. Cote SR, Chitravanshi VC, Bleickardt C, Sapru HN, Kuzhikandathil EV. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors. Behav. Brain. Res. 2014;263:46–50. doi: 10.1016/j.bbr.2014.01.011.
    1. Payer DE, et al. D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia. Neurology. 2016;86:224–230. doi: 10.1212/WNL.0000000000002285.
    1. Waters, N., et al. Pharmacology of IRL790, a psychomotor stabilizer for the treatment of L-dopa induced dyskinesias and psychosis in Parkinson’s disease. Poster (We-66C) presented at Dopamine 2016, Vienna, Austria.
    1. Sun J, Cairns NJ, Perlmutter JS, Mach RH, Xu J. Regulation of dopamine D3 receptor in the striatal regions and substantia nigra in diffuse Lewy body disease. Neuroscience. 2013;248:112–126. doi: 10.1016/j.neuroscience.2013.05.048.
    1. Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69:183–189. doi: 10.1002/syn.21805.
    1. Krishnamoorthy S, et al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson’s disease patients. Park. Relat. Disord. 2016;30:13–17. doi: 10.1016/j.parkreldis.2016.06.005.
    1. Castro-Martínez X. H., et al. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants. Parkinsonism Relat Disord. Published online 12 January 2018.
    1. Griffiths RI, et al. Automated assessment of bradykinesia and dyskinesia in Parkinson’s disease. J. Park. Dis. 2012;2:47–55.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner